TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Dianthus Therapeutics
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

Dianthus Therapeutics reported successful Phase 2 trial results for claseprubart in generalized Myasthenia Gravis, demonstrating promising treatment effects and announcing plans for a Phase 3 trial in 2026.

Insights
DNTH   positive

Presented successful Phase 2 trial data, demonstrated treatment potential, and outlined clear plans for Phase 3 clinical trial with promising preclinical insights